4th Oct 2021 09:41
(Alliance News) - GlaxoSmithKline PLC investee ViiV Healthcare on Monday said it has moved to gain a further US approval for its Triumeq drug cocktail for children with HIV.
Currently, Triumeq, a combination of abacavir, dolutegravir and lamivudine, is backed by the US Food & Drug Administration to treat children weighing over 40 kilogrammes with HIV. ViiV, however, wants to lower that minimum to children weighing over 14 kg.
This will "result in further treatment options for younger children living with HIV", ViiV said.
GSK is the majority-owner of ViiV, with Pfizer Inc and Shionogi & Co Ltd also holding stakes.
GSK shares were 0.1% higher at 1,387.00 pence each in London on Monday morning.
By Eric Cunha; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline